Last updated on November 2017

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter study of the Analgesic Efficacy and Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects with Osteoarthritis Of The Hip Or Knee


Brief description of study

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter study of the Analgesic Efficacy and Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects with Osteoarthritis Of The Hip Or Knee

Detailed Study Description

This is A randomized, double-blind, placebo-controlled, multicenter, parallel-group, study of the efficacy and safety of Tanezumab when administered by SC injection for 16 weeks compared to placebo in subjects osteoarthritis of the Knee or hip. Subjects will receive a total of two injections, separated by 8 weeks.

Clinical Study Identifier: TX11159

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jay Dobson

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »

Christina Stahl

Quality Medical Research
Nashville, TN USA
  Connect »